Results from a blind and a non-blind randomised trial run in parallel: Experience from the Estonian Postmenopausal Hormone Therapy (EPHT) Trial

BMC Medical Research Methodology

Volumn 12, Issue , 2012, Pages

  Veerus, Piret ^a   Fischer, Krista ^b   Hakama, Matti ^c   Hemminki, Elina ^d  

^a NATIONAL INSTITUTE FOR HEALTH DEVELOPMENT   (Estonia)

^b UNIVERSITY OF TARTU   (Estonia)

^c UNIVERSITY OF TAMPERE   (Finland)

^d NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

Author keywords

Blinding; Clinical trial; Internal and external validity

Indexed keywords

ARTICLE; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; ESTROGEN THERAPY; FEMALE; HEALTH STATUS; HUMAN; METHODOLOGY; MIDDLE AGED; PATIENT COMPLIANCE; PATIENT PARTICIPATION; PLACEBO EFFECT; POSTMENOPAUSE; PROPORTIONAL HAZARDS MODEL; RANDOMIZED CONTROLLED TRIAL; REPRODUCIBILITY; SOCIAL CLASS; TREATMENT OUTCOME;

CEREBROVASCULAR DISORDERS; CORONARY DISEASE; DOUBLE-BLIND METHOD; ESTROGEN REPLACEMENT THERAPY; FEMALE; HEALTH STATUS; HUMANS; MIDDLE AGED; PATIENT COMPLIANCE; PATIENT PARTICIPATION; PLACEBO EFFECT; POSTMENOPAUSE; PROPORTIONAL HAZARDS MODELS; REPRODUCIBILITY OF RESULTS; RESEARCH DESIGN; SOCIAL CLASS; TREATMENT OUTCOME;

EID: 84859177226     PISSN: None     EISSN: 14712288     Source Type: Journal    
DOI: 10.1186/1471-2288-12-44     Document Type: Article

References (29)

1. Pragmatic controlled clinical trials in primary care: the struggle between external and internal validity. Godwin M, Ruhland L, Casson I, MacDonald S, Delva D, Birthwhistle R, Lam M, Seguin R, BMC Med Res Methodol 2003 3 28 10.1186/1471-2288-3-28 14690550
2. Randomisation. Altman DG, BMJ 1991 302 1481 1482 10.1136/bmj.302.6791. 1481 1855013
3. Treatment allocation in controlled trials: why randomise? Altman DG, Bland JM, BMJ 1999 318 1209 10221955 (Pubitemid 29201583)
4. Blinding in clinical trials and other studies. Day SJ, Altman DG, BMJ 2000 321 504 10.1136/bmj.321.7259.504 10948038 (Pubitemid 30623610)
5. The CONSORT Statement. http://www.consort-statement.org/consort- statement/ (accessed April 14, 2011)
6. External validity of randomised controlled trials: "to whom do the results of this trial apply?". Rothwell PM, Lancet 2005 365 82 93 10.1016/S0140-6736(04)17670-8 15639683 (Pubitemid 40082150)
7. Assessing the quality of randomized controlled trials: an annotated bibliography of scales and checklists. Moher D, Jadad AR, Nichol G, Penman M, Tugwell P, Walsh S, Controlled Clin Trials 1995 16 62 73 10.1016/0197-2456(94) 00031-W 7743790
8. Section VI: Preparing and maintaining systematic reviews. Cochrane Collaboration handbook Oxford: Cochrane Collaboration, Oxman AD, 1994
9. How to assess the external validity of therapeutic trials: a conceptual approach. Dekkers OM, von Elm E, Algra A, Romijn JA, Vanderbroucke JP, Int J Epidemiol 2010 39 89 94 10.1093/ije/dyp174 19376882
10. Commentary: external validity of results of randomised trials: disentangling a complex concept. Rothwell PM, Int J Epidemiol 2010 39 94 96 10.1093/ije/dyp305 19776246
11. Results from the Estonian Postmenopausal Hormone Therapy (EPHT) Trial [ISRCTN35338757]. Veerus P, Hovi SL, Fischer K, Rahu M, Hakama M, Hemminki E, Maturitas 2006 55 162 173 10.1016/j.maturitas.2006.01.012 16504428 (Pubitemid 44307487)
12. Postmenopausal hormone therapy increases use of health services: experience from the Estonian Postmenopausal Hormone Therapy Trial [ISRCTN35338757]. Veerus P, Fischer K, Hovi SL, Hakama M, Rahu M, Hemminki E, Am J Obstet Gynecol 2006 195 62 71 10.1016/j.ajog.2005.12.037 16813745 (Pubitemid 43927513)
13. Symptom reporting and quality of life in the Estonian Postmenopausal Hormone Therapy Trial. Veerus P, Fischer K, Hovi SL, Karro H, Rahu M, Hemminki E, BMC Women's Health 2008 8 5 10.1186/1472-6874-8-5 22467921 (Pubitemid 351597453)
14. Blinding decreased recruitment in a prevention trial of postmenopausal hormone therapy. Hemminki E, Hovi SL, Veerus P, Sevon T, Tuimala R, Rahu M, Hakama M, J Clin Epidemiol 2004 57 1237 1243 10.1016/j.jclinepi.2004.04.009 15617949 (Pubitemid 40023143)
15. Treatment adherence in the Estonian Postmenopausal Hormone Therapy (EPHT) Trial [ISRCTN35338757]. Vorobjov S, Hovi SL, Veerus P, Pisarev H, Rahu M, Hemminki E, Maturitas 2005 52 286 295 10.1016/j.maturitas.2005.05.001 16055284 (Pubitemid 41562201)
16. Does hormone replacement therapy affect the use of prescription medicines in postmenopausal women: experience from the Estonian Postmenopausal Hormone Therapy Trial [ISRCTN35338757]. Veerus P, Fischer K, Hovi SL, Karro H, Hemminki E, BJOG 2007 114 548 554 10.1111/j.1471-0528.2007.01292.x 17355268 (Pubitemid 46587962)
17. Veerus Piret, The Impact of Postmenopausal Hormone Therapy on Health and Use of Health Services: Experience from the Estonian Postmenopausal Hormone Therapy (EPHT) trial Helsinki: Gummerus 2007
18. World Health Organization, International Statistical Classification of Diseases and Related Health Problems. Tenth Revision Geneva: WHO 1992
19. Estonian Health Insurance Fund. http://www.haigekassa.ee/eng/ (accessed April 14, 2011)
20. Study of completeness of registration at the Estonian cancer registry. Lang K, Mägi M, Aareleid T, Eur J Cancer Prev 2003 12 153 156 10.1097/00008469-200304000-00009 12671539 (Pubitemid 36543429)
21. The R Project for Statistical Computing. http://www.r-project.org/ (accessed April 14, 2011)
22. Evaluating preference effects in partially unblinded, randomised clinical trials. Halpern SD, J Clin Epidemiol 2003 56 109 115 10.1016/S0895-4356(02) 00598-X 12654404 (Pubitemid 36315936)
23. Prescribing placebos: value in the placebo response. Flemming DC, BMJ 2008 337 1252 10.1136/bmj.a1252
24. Risks of estrogen plus progestin therapy: a sensitivity analysis of findings in the Women's Health Initiative randomised controlled trial. Shapiro S, Climacteric 2003 6 302 310 15006251 (Pubitemid 38112900)
25. Hormone replacement therapy and acute coronary outcomes: methodological issues between randomised and observational studies. Garbe E, Suissa S, Hum Reprod 2004 19 8 13 10.1093/humrep/deh022 14688150 (Pubitemid 38072000)
26. Empirical evidence of bias: dimensions of methodological quality associated with estimates of treatment effects in controlled trials. Schulz KF, Chalmers I, Hayes R, Altman DG, JAMA 1995 273 408 412 10.1001/jama.1995. 03520290060030 7823387
27. Impact of allocation concealment on conclusions drawn from meta-analyses of randomized trials. Pildal J, Hrábjartsson A, Jørgensen KJ, Hilden J, Altman DG, Gøtzsche PC, Int J Epidemiol 2007 36 847 857 10.1093/ije/dym087 17517809 (Pubitemid 47394153)
28. Why we need observational studies to evaluate the effectiveness of health care. Black N, BMJ 1996 312 1215 1218 10.1136/bmj.312.7040.1215 8634569 (Pubitemid 26136714)
29. Patients' preferences and randomised trials. Silverman WA, Altman DG, Lancet 1996 347 171 174 10.1016/S0140-6736(96)90347-5 8544555 (Pubitemid 26025160)